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Societal relevance
Prevalence and burden of skeletal muscle dysfunction
Aging as well as several chronic diseases, such as chronic obstructive pulmonary 
disease (COPD), chronic kidney disease, type II diabetes and chronic heart failure, 
are characterized by a decline in peripheral muscle mass and a reduced number 
and impaired functionality of skeletal muscle mitochondria, primarily in the lower 
limbs [1-4]. The latter is associated with a reduced capacity of the muscle to produce 
energy. These skeletal muscle abnormalities ultimately dramatically affect the 
quality of life of these patients and are associated with increased morbidity and 
even higher mortality [5-7]. Indeed, good physical performance and muscle health 
strongly correlate with the ability to perform daily life activities, which is positively 
associated with quality of life and represses healthcare costs [8]. Indicative of the 
colossal impact of the abovementioned muscle abnormalities, sarcopenia defined 
as the loss of muscle mass and muscle function as a result of ageing, is highly 
prevalent in healthy aged individuals (10% [9]). Alarmingly, sarcopenia is even more 
prevalent in patients suffering from chronic diseases, such as type II diabetes and 
COPD [10-12] and numbers are predicted to rise further in the near future [13]. 
Sarcopenia is thus highly prevalent and, as stated above, correlates with an inability 
to adequately perform daily life tasks which ultimately leads to a reduced social 
status and increased hospitalization [14]. In 2014, the costs of sarcopenia-related 
hospitalization in the United States was estimated to be $40.4 billion [15]. Although 
Bruyère et al. could not make definitive conclusions regarding the economic burden 
of sarcopenia, because the studies used were heterogeneous in the assessment of 
sarcopenia and the type of costs evaluated, their systematic review gives a recent 
overview of several papers indicating elevated healthcare-cost in sarcopenic 
individuals. In addition, already in 2000, Janssen et al. estimated that a 10% reduction 
in the prevalence of sarcopenia in the United States alone would save $1.1 billion in 
healthcare-related expenses per year [16]. Treatment or even prevention of skeletal 
muscle impairments can therefore contribute significantly to increasing quality of life 
of large groups of patients and can help with decreasing the massive healthcare costs 
associated with (the management of) chronic diseases [17, 18]. Besides the high 
prevalence of skeletal muscle abnormalities, the above-mentioned diseases are also 
often associated with a high cardiometabolic risk. For example, COPD patients have 
an increased risk for the development of cardiovascular disease [19]. Interestingly, 
reduced skeletal muscle oxidative phenotype (OXPHEN) has been suggested as a 
major driver of increased cardiometabolic risk in COPD [20] and type II diabetes [21, 
22]. This further stresses the need to minimize skeletal muscle abnormalities and 
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thereby reduce cardiometabolic disease-related healthcare costs in these patient 
populations [23].
Future perspective for GSK-3β and TFEB to alleviate muscle abnormalities
In this thesis, we describe a previously unknown role for glycogen synthase 
kinase (GSK)-3β in the molecular regulation of mitochondrial biogenesis and 
oxidative energy metabolism in skeletal muscle. We unraveled that inactivation of 
GSK-3β activated peroxisome proliferator-activated receptor-γ co-activator-1 
(PGC-1)α gene expression via transcription factor EB (TFEB), which resulted in 
enhanced mitochondrial biogenesis and oxidative substrate use in skeletal muscle. 
This indicates that both GSK-3β as well as TFEB may serve as potential targets for 
therapeutic intervention to alleviate abnormalities at the level of the mitochondrion 
in skeletal muscle during ageing or in chronic disease. However, the relevance or 
efficacy of specific GSK-3β inhibitors or TFEB agonists in this context remains to 
be explored in more detail. Moreover, it has been reported that the inhibitory 
phosphorylation of GSK-3β and nuclear abundance of TFEB increase during 
physical activity. Combined with the data presented in this thesis, this indicates that 
improving muscle OXPHEN via modulation of the GSK-3β-TFEB-PGC-1α pathway 
can be achieved by adopting a healthier and more active lifestyle. As a long-term 
perspective, the knowledge gained by research described in this thesis could aid in 
the development of GSK-3β inhibitors, TFEB agonists or lifestyle interventions aiming 
to alleviate muscle abnormalities in the above-mentioned conditions.
Treatment strategies for increasing muscle oxidative 
phenotype
Exercise and exercise mimetics
Physical exercise is the most common and effective method to increase skeletal 
muscle health. However, exercise training is not always feasible in humans due to 
disease-related symptoms or age-related frailty. In addition, lifestyle changes are 
particularly hard to accomplish in elderly [24]. Nonetheless, exercise training or 
increased loading of skeletal muscle are highly effective evidence-based intervention 
methods for improving skeletal muscle function in several chronic conditions, 
including COPD [25]. However, the anabolic and mitochondrial response to exercise 
training is often blunted in COPD patients [26] as well as during aging [27, 28]. 
Alterations in the abundance or activity of TFEB in these conditions might underlie this 
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mal-adaptability, because TFEB knock-out mice have been shown to have a reduced 
ability to increase mitochondrial function and maintain the same exercise capacity 
compared to control animals. This makes them unable to fully benefit from exercise in 
terms mitochondrial regeneration [29], which speculatively could result in a blunted 
anabolic response. In this context, pharmacological activation of the pathways 
controlling muscle OXPHEN and muscle mass (so called ‘exercise-mimetics’) may 
prove beneficial to alleviate skeletal muscle abnormalities in the above-mentioned 
disorders and the aging population [30]. The mechanistic insight in the regulation 
of skeletal muscle PGC-1α expression gained in this thesis suggests a potential role 
for specific GSK-3β inhibitors or TFEB agonists as exercise-mimetics. Although the 
effects of inactivation of GSK-3β on mitochondrial biogenesis and oxidative energy 
metabolism and the involvement of TFEB herein needs to be studied in humans, the 
promising potential of GSK-3β inhibitors for clinical implication is clear.
Pharmacological potential of GSK-3β inhibitors 
In order to verify the importance of GSK-3β in the (dys)regulation of skeletal 
muscle mitochondrial biogenesis and energy metabolism, it needs to be elucidated 
whether or not GSK-3β abundance or activity is altered in skeletal muscle in the 
above-mentioned human conditions associated with loss of muscle OXPHEN. 
In this context, it has been shown that the abundance and activity of GSK-3β is 
higher in skeletal muscle of obese type II diabetic patients compared with lean and 
weight-matched non-diabetic subjects [31]. In addition, GSK-3β phosphorylation 
was found to be reduced (indicating increased GSK-3β activity) in skeletal muscle 
of pregnancy-associated diabetes mellitus patients [32]. If GSK-3β activity is also 
increased in skeletal muscle of COPD patients is unclear. Several studies reported 
contradicting evidence on the phosphorylation status of GSK-3β in skeletal muscle of 
COPD patients. Indeed, unaltered [33, 34] and increased [35] levels of phosphorylated/
inactivated (Ser9) GSK-3β have both been reported in skeletal muscle of COPD 
patients. Literature on the activity of GSK-3β in skeletal muscle in chronic human 
diseases is thus scarce and contradictory and needs to be investigated in closer detail. 
Furthermore, it needs to be elucidated if structural absence of GSK-3β (in ablation 
modalities) or short-term acute inactivation of GSK-3β exert similar effects on TFEB 
nuclear translocation. To date, several experimental studies reveal that inactivation 
of GSK-3β in skeletal muscle is sufficient for nuclear translocation and activation of 
TFEB. Besides the effect of inactivation of GSK-3β on TFEB nuclear translocation in 
healthy conditions, these effects have not been verified in experimental models of 
chronic disease associated with reduced mitochondrial biogenesis. In order to fully 
exploit the benefits of exercise on muscle function, specific inhibition of GSK-3β 
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(or activation of TFEB) combined with an exercise protocol may be a potential novel 
treatment strategy [29]. Indicative of the therapeutic potential of GSK-3β inhibition 
in augmenting muscle functionality, lithium chloride (LiCl; an inhibitor of GSK-3) 
improved muscle strength and muscle mass in a murine muscle dystrophy model 
[36]. However, whether or not pharmacological inhibition of GSK-3β can rescue 
mitochondrial abnormalities in skeletal muscle remain to be investigated. Therefore, 
new studies should focus on the effect of exercise and pharmacological inhibition 
of GSK-3β on TFEB nuclear translocation in skeletal muscle in health and disease. In 
order to accomplish this, placebo-controlled pilot experiments aiming to investigate 
the effect of GSK-3β inhibitors in combination with or without exercise training 
on skeletal muscle mitochondrial biogenesis should reveal the clinical potential of 
GSK-3β inhibitors. Interestingly, lithium is clinically approved and often used to treat 
bipolar disorder [37]. However, some minor side effects of lithium treatment have 
been reported [38]. The clinical use of lithium indicates that lithium as well as more 
specific GSK-3β inhibitor are likely safe for human application. In this thesis, we report 
that GSK-3β inactivation enhanced TFEB nuclear translocation. In addition, TFEB was 
required for the inactivation of GSK-3β-mediated induction of PGC-1α, hence TFEB 
agonist might also be a promising pharmacological intervention aiming to induce 
muscle PGC-1α levels and thereby enhance muscle mitochondrial biogenesis.
Pharmacological potential for TFEB agonists
The role of TFEB in the regulation of PGC-1α and the subsequent control over 
mitochondrial biogenesis and oxidative energy metabolism was only recently 
discovered [29]. Despite this, several studies using multiple cell-types now support 
that nuclear translocation of TFEB, or other microphthalmia/TFE (MiT) family 
members, increases the expression of PGC-1α and enhance mitochondrial biogenesis 
[29, 39, 40]. Interestingly, TFEB agonists that stimulate nuclear translocation are 
being developed and tested [41]. However, if pharmacological activation of TFEB can 
rescue mitochondrial abnormalities in skeletal muscle remains to be investigated. 
In order to accomplish this, placebo-controlled pilot experiments aiming to 
investigate the effect of these compounds on mitochondrial function can be the first 
step to elucidate potential pharmacological potential of TFEB agonist in humans. 
Interestingly, digoxin (chemical TFEB agonist) is clinically approved and thus found 
to be safe for human application. The above-mentioned trials could increase our 
understanding of mitochondrial abnormalities in skeletal muscle within human 
disease and ultimately could reverse aging- or chronic disease-associated skeletal 
muscle mitochondrial deficits.
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A potential role for GSK-3β and TFEB in neurodegenerative 
disorders
Next to skeletal muscle, mitochondria are highly important for the function of a 
myriad of other tissues, for example the brain. Growing lines of evidence suggest 
that mitochondrial dysfunction is involved in neurodegenerative diseases such 
as Parkinson’s, Alzheimer’s and Huntington’s disease. Interestingly, it has been 
proposed that inactivation of GSK-3β, aiming to prevent mitochondrial dysfunction, 
is a potential treatment of neurodegenerative disorders. Pre-clinical data showed 
that pharmacological inhibition of GSK-3β restored mitochondrial biogenesis in 
a mouse model of Parkinson’s disease [42]. Interestingly, Alzheimer’s disease is 
linked to increased activity of GSK-3β in the cortex. Furthermore, reduced levels 
or decreased activity of PGC-1α and TFEB have been associated with Alzheimer’s 
disease progression [43, 44]. This suggest that GSK-3β inhibitors or TFEB agonists 
might also be beneficial for patients with Alzheimer’s disease. Intriguingly, 
pre-clinical data revealed that inhibition of GSK-3β using LiCl reduced both β-amyloid 
as well as tau protein (the two major protein aggregates involved in Alzheimer’s 
disease progression) formation [45, 46]. LiCl treatment was previously reported to 
reduce cognitive decline in Alzheimer’s disease [47]. This indicates that inhibition of 
GSK-3β indeed might be suitable to alleviate the burden of Alzheimer’s disease [48].
Conclusion
The data in this thesis convincingly shows that inactivation of GSK-3β in skeletal 
muscle enhances PGC-1α-mediated mitochondrial biogenesis and oxidative substrate 
metabolism via TFEB. This suggests that both GSK-3β inhibitors as well as TFEB agonists 
are potential therapeutic strategies to treat or even prevent deficits in skeletal muscle 
OXPHEN associated with chronic diseases and aging. In addition, as outlined in the 
general discussion (Chapter 6), GSK-3β is involved in both the regulation of muscle 
mass as well as the regulation of muscle mitochondrial biogenesis and oxidative 
energy metabolism. Thus, specific GSK-3β inhibitors might be beneficial in alleviating 
both abnormalities in muscle mass and muscle OXPHEN that often coincide in 
chronic diseases. To date however it remains unclear if pharmacological inhibition of 
GSK-3β or activation of TFEB can induce skeletal muscle mitochondrial biogenesis 
or enhance oxidative substrate metabolism in a clinical setting. In the future, new 
randomized placebo-controlled human trials should shed light on these remaining 
questions. In addition, particular care should be given to confirm safety of novel 
pharmaceuticals for human application. Furthermore, in order to minimize side 
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effects, the possibility to use specific drug-delivery techniques should be explored to 
transport the medication to the targeted tissue, for example the skeletal muscle [49]. 
Moreover, the beneficial effects of inhibition of GSK-3β on the brain, as discussed 
above, indicates a broader perspective for the pharmacological inhibition of GSK-3β 
in human diseases. Although speculative in nature, the data presented in this thesis 
thus may be applied in several research disciplines beyond skeletal muscle pathology.
